Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q460N3

UPID:
PAR15_HUMAN

ALTERNATIVE NAMES:
ADP-ribosyltransferase diphtheria toxin-like 7; B-aggressive lymphoma protein 3; Poly [ADP-ribose] polymerase 15

ALTERNATIVE UPACC:
Q460N3; J3KR47; Q8N1K3

BACKGROUND:
The enzyme Protein mono-ADP-ribosyltransferase PARP15, known for its roles in mono-ADP-ribosylation, serves as a pivotal regulator within cellular mechanisms. It is identified by several names, including ADP-ribosyltransferase diphtheria toxin-like 7 and B-aggressive lymphoma protein 3, reflecting its diverse functions and significance in biological systems.

THERAPEUTIC SIGNIFICANCE:
The exploration of Protein mono-ADP-ribosyltransferase PARP15's functions offers a promising avenue for the development of novel therapeutic approaches. By elucidating its regulatory roles, researchers can identify new strategies to influence cellular processes for disease treatment and prevention.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.